Embecta Corp.
EMBC Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$6.80
KIRA · Stoqly’s AI analyst, in plain words
- Embecta Corp. had $1.1B of revenue in fiscal 2025, down 3.8% on the year before. Over five years, revenue changed −0.1% a year on average.
- Its operating margin was 22.4%, up 7.6 pts: of every 100 in sales, about 22 is left after running the business.
- Embecta Corp. made $95.4M of net profit in fiscal 2025. From fiscal 2020 to 2025, diluted EPS grew −26.4% a year.
- Free cash flow was $182M in fiscal 2025, 16.9% of revenue.
- Embecta Corp. returned $35.0M to shareholders in fiscal 2025, 19% of free cash flow. The diluted share count rose 1.0%.
- Embecta Corp. owes $1.2B more than it holds in cash, about 4.3 years of operating profit.
Market cap
$398M
P/E
4.6x
Revenue
$1.1B
Net income
$95.4M
Free cash flow
$182M
Operating margin
22.4%
Embecta Corp. in 30 seconds · fiscal 2025
Are sales growing?
−3.8%
No. Sales fell 3.8% last year.
Does it make a profit?
8.8%
A little. It keeps 8.8% of every sale as profit.
Does profit turn into cash?
16.9%
Yes. 16.9% of sales ends up as free cash.
Is debt under control?
4.3x
Heavy. Repaying its debt would take 4.3 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
4.6x
One share costs 4.6 times its yearly profit per share.
What Embecta Corp. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Nov 25, 2025
- Legal name
- Embecta Corp.
- CIK
- 0001872789
Embecta Corp. · EMBC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B |
| Revenue growth | 7.4% | −3.1% | −0.8% | 0.2% | −3.8% |
| Gross margin | 68.7% | 68.6% | 66.9% | 65.5% | 62.6% |
| Operating margin | 42.2% | 27.4% | 19.8% | 14.9% | 22.4% |
| Net income | $415M | $224M | $70.4M | $78.3M | $95.4M |
| Net margin | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| Diluted EPS | $7.28 | $3.89 | $1.22 | $1.34 | $1.62 |
| Cash | |||||
| Cash from operations | $456M | $412M | $67.7M | $35.7M | $192M |
| Capital expenditure | $36.8M | $23.6M | $26.5M | $15.8M | $9.3M |
| Free cash flow | $420M | $389M | $41.2M | $19.9M | $182M |
| FCF margin | 36.0% | 34.4% | 3.7% | 1.8% | 16.9% |
| Dividends paid | $0.0M | $8.6M | $34.4M | $34.5M | $35.0M |
| Share count change | 0.0% | 0.8% | 0.5% | 1.0% | 1.0% |
| Debt and strength | |||||
| Cash and short-term investments | $0.0M | $331M | $326M | $268M | $226M |
| Debt incl. finance leases | $0.0M | $1.6B | $1.6B | $1.6B | $1.4B |
| Shareholders' equity | $594M | −$891M | −$822M | −$738M | −$651M |
| Net debt / EBITDA | 0.0x | 3.8x | 5.2x | 6.6x | 4.3x |
| Current ratio | 1.8x | 2.2x | 2.1x | 2.0x | 2.4x |
| Returns and quality | |||||
| Return on capital | 69.4% | 70.0% | 32.4% | 29.3% | 32.5% |
| Return on equity | 71.1% | — | — | — | — |
| Return on tangible equity | 74.0% | — | — | — | — |
| Piotroski F-score | — | 4 | 3 | 4 | 6 |
| Altman Z'' | — | 1.9 | 1.5 | 1.2 | 2.0 |
Insiders bought, 12 months
$0.6M
4 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Embecta Corp. · EMBC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.80 a share, the company is worth $398M: 4.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001872789). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.